98%
921
2 minutes
20
Background: In 2009, the American Joint Commission on Cancer incorporated the gastrointestinal stromal tumours (GISTs) risk classification into the tumour, node, metastasis (TNM) staging system. We aimed to evaluate the prognostic value of the TNM staging system for GISTs by directly comparing it with the modified National Institutes of Health (NIH) criteria.
Materials And Methods: We /used data from the Surveillance, Epidemiology, and End Results (SEER) database (2010-2019) to retrospectively analyse patients with gastric and small intestinal/colorectal GISTs. Multivariate Cox regression analysis was performed to identify independent prognostic factors for cancer-specific survival (CSS). To assess the predictive performance of the TNM staging system and the modified NIH criteria, we calculated the area under the receiver operating characteristic curve (AUC), concordance index (C-index), Akaike information criterion (AIC), and Bayesian information criterion (BIC).
Results: Of the 3,034 patients included, 2,106 had gastric GISTs and 928 had small intestinal/colorectal GISTs. Multivariate Cox analysis revealed that TNM stage was an independent prognostic factor for CSS. According to the modified NIH criteria, both the overall and subgroup cohorts exhibited better CSS in the low-risk group than that in the very low-risk group. In contrast, for the TNM staging system, the difference in CSS between stages IIIA and IIIB were not statistically significant (all P>0.05). Notably, only 2 of the 928 patients with small intestinal/colorectal GISTs met the modified NIH criteria for intermediate risk. In the gastric GISTs cohort, the AUC, C-index, AIC, and BIC values for the TNM staging system and the modified NIH criteria were similar. However, in the small intestine and colorectal GISTs cohort, the TNM staging system demonstrated better discriminatory performance with higher AUC and C-index and lower AIC and BIC values compared with the modified NIH criteria.
Conclusions: Regarding prognostic evaluation, the TNM staging system was comparable to the modified NIH criteria for patients with gastric GISTs, but it outperformed the modified NIH criteria in the prediction of outcomes for patients with small intestine and colorectal GISTs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12401700 | PMC |
http://dx.doi.org/10.3389/fonc.2025.1622777 | DOI Listing |
Front Oncol
August 2025
Department of Surgery, Hebei Medical University, Shijiazhuang, Hebei, China.
Background: Tumor deposit (TD) is an independent risk factor associated with recurrence or metastasis for patients with colorectal cancer (CRC). The scenario in which both TD and lymph node metastasis (LNM) are positive is not clearly illustrated by the current TNM staging system. Simply treating one TD as one or two LNMs by a weighting factor is inappropriate.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
September 2025
Department of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Marburg, Germany.
Introduction: The prognosis of anaplastic thyroid carcinoma (ATC) remains poor. Mutation-based targeted therapies and immune checkpoint inhibitors (ICI) have gained increasing importance in the treatment of advanced tumor stages. This study aimed to investigate whether mutation-based neoadjuvant therapy can convert an initially unresectable tumor into a resectable state, optimizing local tumor control and prolonging overall survival.
View Article and Find Full Text PDFPLoS One
September 2025
Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Volumetric modulated arc therapy (VMAT) for lung cancer involves complex multileaf collimator (MLC) motion, which increases sensitivity to interplay effects with tumour motion. Current dynamic conformal arc methods address this issue but may limit the achievable dose distribution optimisation compared with standard VMAT. This study examined the clinical utility of a VMAT technique with monitor unit limits (VMATliMU) to mimic conformal arc delivery and reduce interplay effects while maintaining plan quality.
View Article and Find Full Text PDFPLoS One
September 2025
Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
Background: Current aftercare in breast cancer survivors aims to detect local recurrences or contralateral disease, while the detection of distant metastases has not been a central focus due to a lack of evidence supporting an effect on overall survival. However, the data underpinning these guidelines are mainly from trials of the 1980s/1990s and have not been updated to reflect the significant advancements in diagnostic and therapeutic options that have emerged over the past 40 years. In this trial, the aim is to test whether a liquid biopsy-based detection of (oligo-) metastatic disease at an early pre-symptomatic stage followed by timely treatment can impact overall survival compared to current standard aftercare.
View Article and Find Full Text PDFJ Cancer Res Clin Oncol
September 2025
Institute for Community Medicine, Section Epidemiology of Health Care and Community Health, University Medicine Greifswald, Greifswald, Germany.
Purpose: The German sector-based healthcare system poses a major challenge to continuous patient monitoring and long-term follow-up, both essential for generating high-quality, longitudinal real-world data. The national Network for Genomic Medicine (nNGM) bridges the inpatient and outpatient care sectors to provide comprehensive molecular diagnostics and personalized treatment for non-small cell lung cancer (NSCLC) patients in Germany. Building on the established nNGM infrastructure, the DigiNet study aims to evaluate the impact of digitally integrated, personalized care on overall survival (OS) and the optimization of treatment pathways, compared to routine care.
View Article and Find Full Text PDF